Prospective, active controlled 12-week study to evaluate effect of exenatide on obesity and non alcoholic fatty liver disease (NAFLD) with elevated liver enzymes in patients with type 2 diabetes mellitus

Trial Profile

Prospective, active controlled 12-week study to evaluate effect of exenatide on obesity and non alcoholic fatty liver disease (NAFLD) with elevated liver enzymes in patients with type 2 diabetes mellitus

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Oct 2015

At a glance

  • Drugs Exenatide (Primary) ; Insulin aspart; Insulin glargine
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Most Recent Events

    • 23 Oct 2015 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top